- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Intensive care unit
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Pharmacological intervention
- Monoclonal antibodies
- Immunomodulator
- Antineoplastic agent
- Imatinib
- Infliximab